NYSE · DHR
Healthcare · Medical - Diagnostics & Research
$211.81
Down-$0.73 (-0.34%)
Updated Sep 20, 2026, 8:28 AM
SID Score
5.8/10
Composite research score
Smart Money
51/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
DHR closed at $211.81 after 19 trading sessions, down 1.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $212.64 | $214.98 | $210.10 | $211.81 | 8.84M |
| Sep 17, 2026 | $210.48 | $213.27 | $206.6901 | $212.50 | 6.18M |
| Sep 16, 2026 | $209.67 | $211.98 | $206.675 | $208.36 | 3.57M |
| Sep 15, 2026 | $203.08 | $209.55 | $202.6201 | $209.36 | 3.51M |
| Sep 14, 2026 | $202.48 | $203.81 | $199.09 | $203.25 | 3.43M |
| Sep 11, 2026 | $201.99 | $202.68 | $199.16 | $200.14 | 3.63M |
| Sep 10, 2026 | $202.33 | $203.10 | $200.34 | $200.53 | 3.02M |
| Sep 9, 2026 | $206.00 | $206.05 | $201.95 | $204.85 | 2.77M |
| Sep 8, 2026 | $205.00 | $207.84 | $202.12 | $205.23 | 3.28M |
| Sep 4, 2026 | $207.19 | $208.70 | $205.23 | $207.66 | 2.9M |
| Sep 3, 2026 | $210.51 | $213.13 | $206.05 | $211.03 | 2.42M |
| Sep 2, 2026 | $207.77 | $212.7793 | $206.10 | $209.91 | 2.95M |
| Sep 1, 2026 | $214.74 | $215.00 | $206.55 | $206.93 | 3.15M |
| Aug 31, 2026 | $213.45 | $215.385 | $212.22 | $213.56 | 3.61M |
| Aug 28, 2026 | $215.10 | $217.04 | $212.8502 | $216.07 | 2.86M |
| Aug 27, 2026 | $214.78 | $218.57 | $213.092 | $215.68 | 2.93M |
| Aug 26, 2026 | $213.23 | $216.8499 | $212.81 | $215.36 | 2.53M |
| Aug 25, 2026 | $213.88 | $216.77 | $212.24 | $215.97 | 2.34M |
| Aug 24, 2026 | $218.33 | $218.34 | $213.88 | $215.11 | 2.51M |
The latest Smart Investors Daily articles mentioning DHR.
DHR research
Company profile and research snapshot.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 22, 2026 | RBC Capital | Outperform | — |
| Jul 22, 2026 | Guggenheim | Buy | — |
| Jul 22, 2026 | Stifel | Buy | — |
| Jul 22, 2026 | TD Cowen | Buy | — |
| Jul 22, 2026 | Wells Fargo | Equal-Weight | — |
Generated Sep 19, 2026, 9:18 PM
Danaher Corporation shares declined 0.34% today amid modest market activity and mixed analyst commentary comparing its performance to peers. The decline appears driven more by broad market sentiment and relative positioning discussions rather than company-specific negative news.
Bottom line: DHR's modest decline reflects investor indecision rather than fundamental deterioration, with the stock caught between supportive long-term trends and near-term valuation concerns highlighted by peer comparisons. Investors should monitor analyst commentary on growth acceleration and watch for any catalysts that could justify current valuations relative to healthcare peers.
Yahoo · Sep 18, 2026
Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]
Yahoo · Sep 18, 2026
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Yahoo · Sep 18, 2026
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Benzinga · Sep 16, 2026
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Interpretive context generated from the platform’s current data sources.
Danaher Corporation shares closed at $211.77, declining 1.12% in the most recent session, per SID market data. Over the trailing one-month period, DHR posted a marginal gain of 0.15%, while the three-month return registered a robust 19.55%, indicating meaningful recovery momentum. On a year-over-year basis, the stock remains down 6.42%, reflecting broader headwinds across the healthcare sector. Technically, DHR trades above both its 50-day moving average of $203.83 and its 200-day moving average of $198.48, suggesting the medium-term trend has turned constructive. However, the 14-day RSI sits at 44.6, positioning the stock in neutral territory with no immediate overbought or oversold signals. According to Massive/Polygon data, average daily volume stands at approximately 4.18 million shares. Danaher's beta of 0.923 indicates slightly lower volatility than the broader market, consistent with its defensive healthcare positioning and diversified life sciences portfolio.
Danaher Corporation carries a market capitalization of approximately $166.5 billion, positioning it among the largest companies in the healthcare sector, per SID market data. The stock's trailing price-to-earnings ratio stands at 47.14, a premium multiple that reflects the market's expectation of earnings recovery following the post-pandemic normalization in its bioprocessing segment. The PEG ratio of 14.87 suggests the current P/E is elevated relative to near-term earnings growth projections, according to SEC filings and consensus estimates. DHR trades at a price-to-book ratio of 3.23, which accounts for substantial goodwill and intangible assets accumulated through its acquisition-driven growth strategy. The company offers a modest dividend yield of 0.53%, consistent with its capital allocation philosophy that prioritizes reinvestment and M&A over shareholder distributions. Relative to healthcare sector peers, Danaher's valuation metrics reflect a premium tied to its Danaher Business System and long-term compounding track record.
Danaher Corporation's composite smart money score stands at 51 out of 100, reflecting a neutral overall signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating strong conviction among large asset managers and fund complexes. In contrast, insider activity scores 4.9 out of 25, though recent filing data reveals notable buying pressure — SEC Form 4 filings show 20 insider transactions over the past 90 days, with 17 classified as purchases and only 3 as sales. This buy-to-sell ratio of nearly 6-to-1 suggests management and board members perceive value at current price levels. The dark pool activity score of 8.5 out of 25 indicates moderate off-exchange institutional trading volume. Congressional trading activity scores 12.8 out of 25, reflecting middling interest from members of Congress in disclosed positions. The divergence between maximum institutional conviction and the neutral composite score is driven primarily by the lower dark pool and insider raw scores, though the directional skew in insider transactions warrants monitoring as a potential leading indicator.
Danaher Corporation has delivered three consecutive quarters of earnings beats, according to company earnings reports. In the most recent reported quarter, DHR posted earnings per share of $1.94 against analyst estimates of $1.84, representing a positive surprise of $0.10. The prior quarter saw EPS of $2.06 versus estimates of $1.94, a beat of $0.12, while the quarter before that recorded $2.23 against the $2.17 consensus, a $0.06 upside. This consistent pattern of modest outperformance suggests disciplined operational execution through the Danaher Business System. Looking ahead, analysts project EPS of $1.92 for the upcoming quarter with results expected on October 20, 2026. The sequential decline in estimates from $1.94 to $1.92 reflects anticipated seasonal patterns in the life sciences and diagnostics segments. The narrowing magnitude of earnings surprises across recent quarters — from $0.12 to $0.10 — suggests analyst models are converging toward the company's actual run rate.
Wall Street consensus on Danaher Corporation skews bullish, with the majority of recent analyst actions reiterating positive ratings, per SID consensus data. On July 22, 2026, four firms maintained favorable positions: Guggenheim, Stifel, and TD Cowen each reiterated Buy ratings, while RBC Capital maintained its Outperform designation. Wells Fargo stood as the lone neutral voice, reiterating its Equal-Weight rating. Notably, all five actions were maintenance calls rather than upgrades or downgrades, suggesting analysts view the current trajectory as consistent with prior expectations following the latest earnings report. The clustering of reiterations on the same date — July 22, 2026 — aligns with post-earnings coverage updates, according to Wall Street analyst reports. The 4-to-1 ratio of bullish versus neutral ratings among recent coverage reflects broad confidence in Danaher's long-term positioning within life sciences and diagnostics, though the absence of any new price target revisions limits the informational signal from this round of updates.
The latest Smart Investors Daily articles mentioning DHR.
